Jordan Appleyard, Clinical Research Fellow at Yorkshire Cancer Research, shared on LinkedIn:
“Really pleased to share our latest work, now published in Colorectal Disease.
Systemic inflammation and prognosis in patients with RAS/BRAF wild-type metastatic colorectal cancer receiving anti-EGFR therapy: A real-world cohort study.
In this retrospective analysis, we assessed whether routinely available markers of systemic inflammation could provide useful prognostic information in patients with RAS/BRAF wild-type metastatic colorectal cancer receiving anti-EGFR therapy.
Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were independently associated with overall survival and progression-free survival, while the systemic immune-inflammation index (SII) showed the strongest prognostic signal. These simple blood-based markers may help support prognostic assessment in this patient group.
A huge thank you to my co-authors Faye Elliott, Nancy Sapanara, Liping Zhang, Uday Kurkure, Jenny Seligmann, Nick West, Kandavel Shanmugam, Philip Quirke and Christopher Williams, and to everyone involved across the N6 Collaboration.”
Title: Systemic inflammation and prognosis in patients with RAS/BRAF wild-type metastatic colorectal cancer receiving anti-EGFR therapy: A real-world cohort study
Authors: Jordan W. Appleyard, Faye Elliott, Nancy L. Sapanara, Liping Zhang, Uday Kurkure, Jenny F. Seligmann, Nicholas P. West, Kandavel Shanmugam, Philip Quirke, Christopher J. M. Williams
Read the full article here.
You may also be interested in: Early-Onset Colorectal Cancer: Recognition, Workup and Treatment Selection
